ArticleBlood cancer journal2018
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 47 citations in OpenAlex.
- Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study.Blood cancer journal · 2025Article
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.Leukemia · 2022Article
- Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.Molecular oncology · 2022Article
- Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.International journal of cancer · 2021Review
- Increased expression of IFI16 predicts adverse prognosis in multiple myeloma.The pharmacogenomics journal · 2021Article
- Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.Human molecular genetics · 2021Article
- From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics.Scientific reports · 2021Article
- Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021Review
- Genome-Wide Association Analyses Identify Variants inFrontiers in genetics · 2021Article
- Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.Frontiers in oncology · 2021Article
- Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.Blood · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 6 countries.
Molly WentDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK. molly.went@icr.ac.uk.
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-6133-0164
Helen SpeedyDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Nicola J SunterNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Asta FörstiGerman Cancer Research Center, 69120, Heidelberg, Germany.
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0001-9663-4611
David C JohnsonDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0003-0887-3343
Fabio MirabellaDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0003-3785-6868
Amy HolroydDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Ni LiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Giulia OrlandoDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Niels WeinholdMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Mark van DuinDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Bowang ChenGerman Cancer Research Center, 69120, Heidelberg, Germany.
Jonathan S MitchellDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Larry MansouriDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 75105, Uppsala, Sweden.
Gunnar JuliussonLund Strategic Research Center for Stem Cell Biology and Cell Therapy, Hematology and Transplantation, Lund University, Lund, Sweden.
Karin E SmedbyUnit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Sandrine JayneErnest and Helen Scott Haematological Research Institute, Leicester University, Leicester, UK.
Aneela MajidErnest and Helen Scott Haematological Research Institute, Leicester University, Leicester, UK.
Claire DeardenDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
David J AllsupDepartment of Haematology, Hull Royal Infirmary, Hull, UK.
James R BaileyHull York Medical School and University of Hull, Hull, UK.
Guy PrattDepartment of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
Chris PepperDepartment of Haematology, School of Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0003-3603-8839
Chris FeganCardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.
Richard RosenquistDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 75105, Uppsala, Sweden.
Rowan KuiperDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Owen W StephensMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Uta BertschGerman Cancer Research Center, 69120, Heidelberg, Germany.
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Hermann EinseleUniversity Clinic of Würzburg, 97080, Würzburg, Germany.
Walter M GregoryClinical Trials Research Unit, University of Leeds, Leeds, LS2 9PH, UK.ORCID http://orcid.org/0000-0003-2641-8416
Jens HillengassDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Per HoffmannInstitute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Graham H JacksonRoyal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK.
Karl-Heinz JöckelInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jolanta NickelDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Markus M NöthenInstitute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Miguel Inacio da Silva FilhoGerman Cancer Research Center, 69120, Heidelberg, Germany.
Hauke ThomsenGerman Cancer Research Center, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5951-3116
Brian A WalkerMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Annemiek BroylDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Faith E DaviesMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Markus HanssonCenter for Primary Health Care Research, Lund University, SE-205 02, Malmo, Sweden.ORCID http://orcid.org/0000-0002-7715-4548
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Martin J S DyerErnest and Helen Scott Haematological Research Institute, Leicester University, Leicester, UK.
Martin KaiserDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Gareth J MorganMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Kari HemminkiGerman Cancer Research Center, 69120, Heidelberg, Germany.
Björn NilssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund University, Lund, Sweden.
Daniel CatovskyDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
James M AllanNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-5268-0242
Institute of Cancer Research · GBGerman Cancer Research Center · DEErasmus MC Cancer Institute · NLHeidelberg University · DEUniversity of Arkansas for Medical Sciences · USUniversity of Leicester · GBLund University · SENewcastle University · GBUniversity of Bonn · DEUppsala University · SEBroad Institute · USCardiff University · GBHeartlands Hospital · GBHull Royal Infirmary · GBKarolinska Institutet · SENational Health Service · GBRoyal Victoria Infirmary · GBUniversity of Duisburg-Essen · DEUniversity of Hull · GBUniversity of Leeds · GB
Funding
Tumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI YACCOBY, SHMUEL · 1993 to 2013
$49.7MUnderstanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2018 to 2026
$23.0MEpidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MImputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9MCancer Research UK 14136Cancer Research UK A16561Cancer Research UK C1287/A10118Cancer Research UK C1287/A16563Cancer Research UK C1298/A8362Cancer Research UK C16913/A6135Cancer Research UK C5047/A10692Cancer Research UK C5047/A3354Cancer Research UK C5047/A7357Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0100132Medical Research Council G1001799Medical Research Council MC_U132670597Medical Research Council MR/M012190/1NCI NIH HHS P01 CA055819NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INIGMS NIH HHS P20 GM125503Wellcome TrustWellcome Trust 090532/Z/09/Z
Abstract
The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (R
Indexed as
Genetic Association StudiesGenetic Predisposition to DiseaseAllelesCase-Control StudiesDatabases, GeneticGenetic LinkageGenome-Wide Association StudyHumansLeukemia, Lymphocytic, Chronic, B-CellLinkage DisequilibriumMultiple MyelomaOrgan SpecificityPolymorphism, Single NucleotideQuantitative Trait Loci
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.